Ondansetron suppository: A randomised, double-blind, double-dummy, parallel-group comparison with oral ondansetron for the prevention of cyclophosphamide induced emesis and nausea

Oncology (Switzerland)

Volumn 54, Issue 5, 1997, Pages 380-386

  Davidson, N G P ^a   Paska, W ^b   Van Belle, S ^c   Goedhals, L ^d   McQuade, B ^b   McRae, J ^b   Bonaventura, B ^e   Boyer, B ^e   Olver, O ^e   Prosser, P ^e   Baumgartner, B ^e   Kienzer, K ^e   Schuller, S ^e   Van Belle, V ^e   Warnier, W ^e   Bekker, B ^e   Mejer, M ^e   Philip, P ^e   Audhuy, A ^e   Corette, C ^e   Dalivoust, D ^e   Lejcune, L ^e   Nouyrigat, N ^e   Soubeyran, S ^e   Tubiana, T ^e   Barten, B ^e   Braumann, B ^e   Christmann, C ^e   Du Bois, D ^e   Hurat, H ^e   Westerhausen, W ^e   Ten Bokkel Huininek, T ^e   Verweij, V ^e   Ashkenazi, A ^e   Inbar, I ^e   Shapira, S ^e   Borge, B ^e   Brunsvig, B ^e   Erikstein, E ^e   Kassa, K ^e   Kvaloy, K ^e   Norunt, N ^e   Goedhals, G ^e   Johnson, J ^e   Agrup, A ^e   Albertsson, A ^e   Carlsson, C ^e   Fomander, F ^e   Malmestrom, M ^e   Svensson, S ^e   Aapro, A ^e   Buser, B ^e   Obrist, O ^e   Sessa, S ^e   Cunninham, C ^e   Davidson, D ^e   Earl, E ^e   Stewart, S ^e   more..

^a NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d National Hospital Bloemfontein   (South Africa)

^e NONE   (United Kingdom)

Author keywords

5 HT3 antagonist; Cyclophosphamide; Emesis; Ondansetron; Suppository

Indexed keywords

CYCLOPHOSPHAMIDE; ONDANSETRON;

ADULT; AGED; ANTIEMETIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUPPOSITORY; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; ONDANSETRON; SUPPOSITORIES; TREATMENT OUTCOME; VOMITING;

EID: 0030824816     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227723     Document Type: Article

References (17)

1. Kris MG, Gralla RJ, Clark RA, et al: Incidence, course and severity of delayed nausea and vomiting following the administration of high dose cisplatin. J Clin Oncol 1985:3:1379-1384.
2. Priestman T: Radiation induced emesis. Clinician 1988:6:40-43.
3. De Mulder P, Seynaeve C, Vermorken J, van Liessum PA, Mols-Jevdevic S, Lane Allman E, Beranek P, Verweij J: Ondansetron compared with high-dose metoclopramide in the prophylaxis of acute and delayed cisplatin-induccd nausea and vomiting - A multicentre randomised, double-blind, crossover study. Ann Intern Med 1990;113:834-840.
4. Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, Pujade-Lauraine E, Paule B, Paes D, Bons J: Comparison of the 5-hydroxytrypta-minc (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990;322:816-821.
5. Schmoll HJ: The role of ondansetron in the treatment of emesis induced by non-cisplatin containing chemotherapy regimens. Eur J Cancer Clin Oncol 1989:25:535-539.
6. Priestman TJ, Roberts JT, Lucraft H, Collis CH, Adams M, Upadhyaya BK, Priestman S: Results of a randomised double-blind comparative study of ondansetron and mctoclopram-ide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. Clin Oncol 1990;2:71-75.
7. Fraschini G, Ciociola A, Esperanza L, Templeton D, Holmes FA, Walters RS, Hortobagyi GN: Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubi-cin chemotherapy. J Clin Oncol 1991;9:1268- 1274.
8. Marschner NW, Adler M, Nagel GA, Christ-mann D, Fenzl E, Upadhyaya B: Double-blind, randomised trial of the anti-emetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer 1991:27:1137-1140.
9. Beck TM, Ciociola AA, Jones SE, Harvey WH, Tchekmedyian NS, Chang A, Galvin D, Hart NE and the Ondansetron Study Group: Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 1993:118:407-413.
10. Clavel M, Bonneterre J, d’Allens H, Paillarse JM and the French Ondansetron Study Group: Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. Eur J Cancer 1995:31:15-19.
11. van Elteren PH: On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst 1960;37:351-361.
12. Dicato MA: Oral treatment with ondansetron in an outpatient setting. Eur J Cancer 1991; 27(suppl 1):S18-S19.
13. de Wit R, Beijnen JH, van Tellingen O, Schell-ens JHM, de Boer-Dennert M, Verweij J: Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: A double blind comparative study with ondansetron tablets. Br J Cancer 1996;74:323-326.
14. VanHoogdalem EJ, De Boer AG, Breimer DD: Pharmacokinetics of rectal drug administration. 1. General considerations and clinical applications of centrally acting drugs. Clin Phar-macokinct 1991;21:11-26.
15. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MHN: On the receiving end - Patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203-208.
16. Finlay I: Rational use of anticmctics in the terminally ill. Postgrad Update, December 1991. pp 876-880.
17. Hardy F, Warrington PS, MacPherson JS, Hudson SA, Jefferson GC, Smyth JF: A pharmacokinetic study of high-dose metoclopram-idc suppositories. J Clin Pharmacol Ther 1990; 15:21-24.